BridgeMD
Compares treatment options for Moderate to Severe Plaque Psoriasis
Official title A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
ClinicalTrials.gov ID: NCT06425549
What this study is testing
What is bimekizumab?
bimekizumab is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for moderate to severe plaque psoriasis.
Also referred to as BKZ, UCB4940.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO).
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 6 to 17
You may be able to join if
- Study participant must be 6 to \<18 years of age, inclusive, at the time of signing the informed consent/assent according to local regulation
- Study participant has had a diagnosis of moderate to severe plaque psoriasis (PSO) for at least 3 months prior to the Screening Visit
- Study participant meets the following at both the Screening and Baseline Visits:
- Body surface area (BSA) affected by PSO ≥10%
- . Investigator's Global Assessment (IGA) score ≥3 (on a scale from 0 to 4)
You likely can't join if
- Primary failure (no response within 12 weeks) to 1 or more interleukin-17 (IL-17) biologic response modifiers (eg, brodalumab, ixekizumab...
- Study participant has a presence of guttate, inverse, pustular, or erythrodermic PSO or other dermatological condition that may impact the clinical...
- Study participant has a history of inflammatory bowel disease (IBD) or symptoms suggestive of IBD
- History of active tuberculosis unless successfully treated, latent TB unless prophylactically treated
- Study participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections...
- Study participant has previously received bimekizumab
See the full eligibility criteria
- Study participant must be 6 to \<18 years of age, inclusive, at the time of signing the informed consent/assent according to local regulation
- Study participant has had a diagnosis of moderate to severe plaque psoriasis (PSO) for at least 3 months prior to the Screening Visit
- Study participant meets the following at both the Screening and Baseline Visits:
- Body surface area (BSA) affected by PSO ≥10%
- . Investigator's Global Assessment (IGA) score ≥3 (on a scale from 0 to 4)
- . Psoriasis Area and Severity Index (PASI) score ≥12 OR PASI score ≥10 plus at least 1 of the following: i) Clinically relevant facial involvement ii) Clinically relevant genital involvement iii) Clinically relevant...
- Study participant is a candidate for systemic PSO therapy and/or photo/chemotherapy and for treatment with ustekinumab per labeling
- Study participant has body weight ≥15 kg and body mass index for age percentile of ≥5 at Screening
- Primary failure (no response within 12 weeks) to 1 or more interleukin-17 (IL-17) biologic response modifiers (eg, brodalumab, ixekizumab, secukinumab) OR more than 1 biologic response modifier other than an IL-17
- Study participant has a presence of guttate, inverse, pustular, or erythrodermic PSO or other dermatological condition that may impact the clinical assessment of PSO
- Study participant has a history of inflammatory bowel disease (IBD) or symptoms suggestive of IBD
- History of active tuberculosis unless successfully treated, latent TB unless prophylactically treated
- Study participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections, unusually severe infections)
- Study participant has previously received bimekizumab
- Study participant has previously received ustekinumab
- Study participant has received drugs outside the specified timeframes relative to the Baseline Visit or receives prohibited concomitant treatments
- Study participant has the presence of active suicidal ideation, or positive suicide behavior
- Study participant diagnosed with severe depression in the past 6 months (prior to Screening) should be excluded
- Study participant has a history of psychiatric inpatient hospitalization within the past year before enrolling into the study
The study team makes the final eligibility decision.
Where it's taking place
- Fountain Valley, California, United States
- Los Angeles, California, United States
- Northridge, California, United States
- Miami, Florida, United States
- Indianapolis, Indiana, United States
- Kew Gardens, New York, United States
- Charleston, South Carolina, United States
- Arlington, Texas, United States
- Dallas, Texas, United States
- Brussels, Belgium
- Liège, Belgium
- Mississauga, Canada
- St. John's, Canada
- Plzen-bory, Czechia
- Argenteuil, France
- Nantes, France
- Bad Bentheim, Germany
- Berlin, Germany
- Bonn, Germany
- Dresden, Germany
+ 27 more site(s).
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 6 years to 17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Fountain Valley, California, United States; Los Angeles, California, United States; Northridge, California, United States; Miami, Florida, United States; Indianapolis, Indiana, United States; Kew Gardens, New York, United States and 41 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.